Evidence map›Paper›PMID 33930013›Full record

ArticlePloS one2021

Using control charts to understand community variation in COVID-19.

Moira Inkelas, Cheríe Blair, Daisuke Furukawa, Vladimir G Manuel, Jason H Malenfant, Emily Martin, Iheanacho Emeruwa, Tony Kuo, Lisa Arangua, Brenda Robles and 1 more

Abstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Moira InkelasDepartment of Health Policy and Management, Fielding School of Public Health, University of California Los Angeles, Los Angeles, California, United States of America.ORCID 0000-0003-1963-2430
Cheríe BlairDivision of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America.
Daisuke FurukawaDivision of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America.
Vladimir G ManuelPopulation Health Program, Clinical and Translational Science Institute, University of California Los Angeles, Los Angeles, California, United States of America.
Jason H MalenfantDivision of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America.
Emily MartinDepartment of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America.
Iheanacho EmeruwaPopulation Health Program, Clinical and Translational Science Institute, University of California Los Angeles, Los Angeles, California, United States of America.ORCID 0000-0002-1424-6437
Tony KuoPopulation Health Program, Clinical and Translational Science Institute, University of California Los Angeles, Los Angeles, California, United States of America.ORCID 0000-0002-4120-8559
Lisa AranguaDivision of Chronic Disease and Injury Prevention, Los Angeles County Department of Public Health, Los Angeles, California, United States of America.
Brenda RoblesDivision of Chronic Disease and Injury Prevention, Los Angeles County Department of Public Health, Los Angeles, California, United States of America.
Lloyd P ProvostAssociates for Process Improvement, Austin, Texas, United States of America.

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
NRSA Training CoreTL1TR001883 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ALEX BUI, Nina Thawata Harawa · 2016 to 2026
$8.6M
Postdoctoral Training in Global AIDS Prevention ResearchT32MH080634 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JESSE LAWTON CLARK, Pamina Mae Gorbach · 2007 to 2026
$6.4M
NCATS NIH HHS TL1 TR001883NCATS NIH HHS UL1 TR000124NCATS NIH HHS UL1 TR001881NIMH NIH HHS T32 MH080634
6 · The paper itself

Abstract

Decision-makers need signals for action as the coronavirus disease 2019 (COVID-19) pandemic progresses. Our aim was to demonstrate a novel use of statistical process control to provide timely and interpretable displays of COVID-19 data that inform local mitigation and containment strategies. Healthcare and other industries use statistical process control to study variation and disaggregate data for purposes of understanding behavior of processes and systems and intervening on them. We developed control charts at the county and city/neighborhood level within one state (California) to illustrate their potential value for decision-makers. We found that COVID-19 rates vary by region and subregion, with periods of exponential and non-exponential growth and decline. Such disaggregation provides granularity that decision-makers can use to respond to the pandemic. The annotated time series presentation connects events and policies with observed data that may help mobilize and direct the actions of residents and other stakeholders. Policy-makers and communities require access to relevant, accurate data to respond to the evolving COVID-19 pandemic. Control charts could prove valuable given their potential ease of use and interpretability in real-time decision-making and for communication about the pandemic at a meaningful level for communities.

Indexed as

CaliforniaCitiesCOVID-19HumansModels, StatisticalResidence CharacteristicsSARS-CoV-2

Identifiers

PMID33930013
PMCPMC8087083

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.